Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia

Marco Ferrari; Emilio Bolla; Paola Bortolaso; Camilla Callegari; Nicola Poloni; Sergio Lecchini; Simone Vender; Franca Marino; Marco Cosentino

doi:10.1016/j.psychres.2012.07.002

Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia

Psychiatry Res. 2012 Dec 30;200(2-3):1014-7. doi: 10.1016/j.psychres.2012.07.002. Epub 2012 Aug 16.

Authors

Marco Ferrari¹, Emilio Bolla, Paola Bortolaso, Camilla Callegari, Nicola Poloni, Sergio Lecchini, Simone Vender, Franca Marino, Marco Cosentino

Affiliation

¹ Department of Clinical Medicine- Section Clinical and Experimental Pharmacology, University of Insubria, Via Otorino Rossi 9, 21100 Varese, Italy.

PMID: 22901441
DOI: 10.1016/j.psychres.2012.07.002

Abstract

We investigated the relationships between common polymorphisms in CYP1A2 (CYP1A2(⁎)1C and (⁎)1F), CYP1A2-mRNA levels in circulating lymphocytes and clozapine(CLZ)-induced adverse drug reactions (ADRs) in 34 patients. Patients with ADRs had a higher frequency of CYP1A2 low activity allele combinations (8/12; 67%) and lower CYP1A2-mRNA levels than patients without ADRs (6/22; 27%, P=0.019).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Alleles
Antipsychotic Agents / adverse effects*
Antipsychotic Agents / therapeutic use
Clozapine / adverse effects*
Clozapine / therapeutic use
Cytochrome P-450 CYP1A2 / genetics*
Female
Gene Frequency
Genetic Association Studies
Humans
Male
Middle Aged
Polymorphism, Genetic*
Schizophrenia / drug therapy*
Schizophrenia / genetics*

Substances

Antipsychotic Agents
CYP1A2 protein, human
Cytochrome P-450 CYP1A2
Clozapine